Management of Staphylococcus epidermidis in Urine Culture
Key Clinical Decision Points
- The Infectious Diseases Society of America recommends against treating asymptomatic bacteriuria with S. epidermidis in most populations, as treatment promotes antimicrobial resistance without clinical benefit 1
- The Hospital Infection Control Practices Advisory Committee discourages treatment of single positive cultures when contamination is likely, a principle that extends to urine cultures where S. epidermidis is a common skin contaminant 2, 3
Exceptions: When Treatment IS Indicated
- Treatment of S. epidermidis urinary tract infections is indicated when the patient has clear urinary symptoms and a positive culture, according to the Infectious Diseases Society of America and the American Academy of Pediatrics 1, 4
- The Infectious Diseases Society of America recommends treating S. epidermidis urinary tract infections in patients undergoing endoscopic urologic procedures with anticipated mucosal trauma 1
- The Infectious Diseases Society of America recommends treating asymptomatic bacteriuria in pregnant women, one of the few populations where asymptomatic bacteriuria requires treatment 1
Special Considerations
- Device removal is often necessary for device-related infections, as S. epidermidis produces extracellular slime forming biofilms on indwelling devices, requiring higher antibiotic concentrations to eradicate 5
- The Centers for Disease Control and Prevention recommends against using vancomycin for routine prophylaxis of catheter-associated infections or for treating presumed infections when cultures are negative 2, 3
- The American Academy of Pediatrics recognizes that while S. epidermidis can cause true UTIs in children with anatomic abnormalities, it should not be treated as a first-line pathogen without clear clinical indication 6, 7
- Proper specimen collection technique is essential to minimize contamination, as S. epidermidis is normal skin flora, according to the Hospital Infection Control Practices Advisory Committee 2, 3